<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405808</url>
  </required_header>
  <id_info>
    <org_study_id>RIMON_R_00961</org_study_id>
    <secondary_id>EUDRACT # : 2006-001711-30</secondary_id>
    <nct_id>NCT00405808</nct_id>
  </id_info>
  <brief_title>Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose</brief_title>
  <acronym>PRADO</acronym>
  <official_title>A Pan-European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Impaired Fasting Blood Glucose With or Without Other Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting&#xD;
      Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of&#xD;
      12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with&#xD;
      impaired fasting blood glucose and with or without associated comorbidities.&#xD;
&#xD;
      Main Secondary objectives:&#xD;
&#xD;
      To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist&#xD;
      circumference (WC), body weight, glycemic parameters and lipid parameters.&#xD;
&#xD;
      To assess the safety of 12 months Rimonabant treatment versus placebo in these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    EMEA recommendation to suspend Acomplia marketing authorisation&#xD;
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the co-primary endpoint : FPG, HDL-C and triglyceride levels.</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference and body weight</measure>
    <time_frame>At each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic parameters (FPG, fasting insulinemia, HbA1c), lipid parameters (Total Cholesterol, HDL-C, LDL-C, triglyceride levels), inflammatory parameter (Hs-CRP),</measure>
    <time_frame>All these laboratory parameters will be measured prior to baseline, month 3, month 6 and month 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (IWQOL questionnaire completion)</measure>
    <time_frame>At baseline, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events in each group, including neuro-psychiatric adverse events</measure>
    <time_frame>From the signature of the ICF to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard laboratory assessments</measure>
    <time_frame>Prior to baseline and month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2666</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of one tablet containing 20 mg of Rimonabant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of one Rimonabant placebo tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant</intervention_name>
    <description>Once daily in the morning</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily in the morning</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI ≥ 30Kg/m², or &gt; 27kg/m² if associated with risk factor(s) such as dyslipidemia,&#xD;
             and &lt; 40kg/m²,&#xD;
&#xD;
          -  Waist Circumference &gt; 88 cm in women; &gt; 102 cm in men,&#xD;
&#xD;
          -  Confirmed (by at least 2 measurements) impaired Fasting Plasma Glucose (FPG ≥ 100&#xD;
             mg/dl (5.6 mmol/L) and &lt; 126 mg/dl (7.0 mmol/L) in non diabetic patients,&#xD;
&#xD;
          -  LDL cholesterol up to 155 mg/dl (4.00 mmol/L) including patients on a stable dose of&#xD;
             statin therapy for at least 8 weeks prior to screening,&#xD;
&#xD;
          -  Current treatment with statins and/or ezetimibe and/or antihypertensive therapy must&#xD;
             be at fixed and stable dose for at least 8 weeks prior to screening visit,&#xD;
&#xD;
          -  Patients, who are willing and in the opinion of the Investigator safely assumed to&#xD;
             remain on stable and fixed doses of antihypertensive, and/or statins and/or ezetimibe&#xD;
             without adding additional medications or changing current treatment for the duration&#xD;
             of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed&#xD;
             (excluded by pregnancy test),&#xD;
&#xD;
          -  Absence of medically approved contraceptive methods for female of childbearing&#xD;
             potential,&#xD;
&#xD;
          -  History of very low-calorie diet within 3 months prior to screening visit (lower than&#xD;
             1200 Kcal/day),&#xD;
&#xD;
          -  Weight change &gt; 5 kg within 3 months prior to screening visit,&#xD;
&#xD;
          -  History of surgical procedures for weight loss (e.g., stomach stapling, bypass),&#xD;
&#xD;
          -  History of bulimia or anorexia nervosa as per DSM-IV criteria,&#xD;
&#xD;
          -  Presence of any clinically significant endocrine disease according to the&#xD;
             investigator, in particular known abnormal TSH and free T4 blood level (Patients&#xD;
             treated with thyroid replacement therapy must be on fixed and stable dose for at least&#xD;
             3 months prior to screening and must be in euthyroïd status),&#xD;
&#xD;
          -  Established type 1 or 2 diabetes treated, or with at least 2 measures of fasting blood&#xD;
             glucose ≥ 126 mg/dl /L,&#xD;
&#xD;
          -  Triglyceride level &gt; 400 mg/dL (4.52 mmol),&#xD;
&#xD;
          -  Systolic blood pressure &gt; 160 mm Hg or diastolic blood pressure &gt;100 mmHg at screening&#xD;
             visit,&#xD;
&#xD;
          -  Known severe renal dysfunction (creatinine clearance &lt; 30 ml/min) or nephrotic&#xD;
             syndrome or urinalysis (performed at screening by dipstick) showing 2+ or more&#xD;
             protein,&#xD;
&#xD;
          -  Known severe hepatic impairment or AST and/or ALT &gt; 3 times the upper limit of normal&#xD;
             at screening,&#xD;
&#xD;
          -  Presence of any condition (medical, including clinically significant abnormal&#xD;
             laboratory tests, psychological, social or geographical) actual or anticipated that&#xD;
             the investigator feels would compromise the patient's safety or limit his/her&#xD;
             successful participation to the study. In particular :&#xD;
&#xD;
               -  Cardiac abnormalities: cardiac failure status NYHA III or IV, relevant acute&#xD;
                  abnormal finding seen on ECG at screening or within 6 months before screening,&#xD;
&#xD;
               -  Any current malignancy or any cancer within the past five years (except&#xD;
                  adequately treated basal cell skin cancer or cervix carcinoma in situ),&#xD;
&#xD;
               -  Significant haematology abnormalities (haemoglobin &lt; 100 g/L and/or neutrophils &lt;&#xD;
                  1.5 G/L and/or platelets &lt; 100 G/L),&#xD;
&#xD;
               -  Acute psychiatric disorders or mental condition which could interfere with the&#xD;
                  patient's compliance or safe participation in the study,&#xD;
&#xD;
               -  Patient treated for epilepsy,&#xD;
&#xD;
          -  Ongoing major depressive illness,&#xD;
&#xD;
          -  Uncontrolled psychiatric illness,&#xD;
&#xD;
          -  History of alcohol or other substance abuse,&#xD;
&#xD;
          -  Hypersensitivity /intolerance to the active substance or to any of the excipients such&#xD;
             as lactose,&#xD;
&#xD;
          -  Administration of any investigational treatment (drug or device) within 30 days prior&#xD;
             to screening,&#xD;
&#xD;
          -  Previous participation in a Rimonabant study or previous administration of Rimonabant,&#xD;
&#xD;
          -  Administration of any of the following within 3 months prior to screening visit:&#xD;
&#xD;
               1. Anti obesity drugs (eg, sibutramine, orlistat),&#xD;
&#xD;
               2. Other drugs for weight reduction (phentermine, amphetamines),&#xD;
&#xD;
               3. Herbal preparations for weight reduction,&#xD;
&#xD;
               4. Nicotinic acid, fibrates or bile acid sequestrants ,&#xD;
&#xD;
               5. Prolonged use (more than one week) of systemic corticosteroids, neuroleptics.&#xD;
&#xD;
               6. Omega-3 fatty acid approved medication&#xD;
&#xD;
          -  Ongoing antidepressive treatment(including bupropion)&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Pilorget, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kallithea</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Lysaker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Luxembourg</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Slovenia</country>
  </removed_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>November 28, 2006</study_first_submitted>
  <study_first_submitted_qc>November 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <last_update_submitted>January 25, 2011</last_update_submitted>
  <last_update_submitted_qc>January 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

